Nonetheless, these findings argue for the benefits of improved seizure control on SUDEP risk and are reassuring regarding polytherapy and SUDEP risk. The magnitude of the effect in this study is difficult to ignore. Some healthcare providers have developed a sort of therapeutic nihilism regarding polytherapy trials because existing data suggest that few additional refractory epilepsy patients are rendered seizure-free by these efforts. However, every change that reduces medication side effects or reduces seizure frequency is an incremental gain, and perhaps, considering the current study, might also have an effect on the risk of SUDEP. Further efforts to better understand how to mitigate the risk of SUDEP are needed.
展开▼
